# Lykos Therapeutics

the FDA rejected its New Drug Application for MDMA-assisted therapy for PTSD in August 2024 following an advisory committee review; the company restructured, cutting roughly 75% of its workforce, and as of a May 2026 status update remains focused on addressing the FDA's concerns rather than holding an approval.

Source: https://en.bioecon.ru/companies/lykos-therapeutics/
Updated: 2026-07-04

- Country: United States

## Technologies

- [Psychedelic medicine & neuropsychiatric biologics](https://en.bioecon.ru/technology/psychedelic-medicine-neuropsychiatric-biologics/)